These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
391 related articles for article (PubMed ID: 30838554)
1. Lipoprotein(a) and mortality-a high risk relationship. Klingel R; Heibges A; Fassbender C Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):13-19. PubMed ID: 30838554 [TBL] [Abstract][Full Text] [Related]
2. Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels. Schettler VJJ; Neumann CL; Peter C; Zimmermann T; Julius U; Hohenstein B; Roeseler E; Heigl F; Grützmacher P; Blume H; Klingel R; Vogt A; Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):33-38. PubMed ID: 30838552 [TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis. Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445 [TBL] [Abstract][Full Text] [Related]
4. Lipoprotein apheresis for Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease--Additional particular aspects of the Pro(a)LiFe multicenter trial. Klingel R; Heibges A; Fassbender C Atheroscler Suppl; 2015 May; 18():35-40. PubMed ID: 25936302 [TBL] [Abstract][Full Text] [Related]
5. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines. Klingel R; Heibges A; Fassbender C; Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214 [TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942 [TBL] [Abstract][Full Text] [Related]
7. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both? Schettler VJJ; Ringel J; Jacob S; Julius U; Klingel R; Heigl F; Roeseler E; Grützmacher P; Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860 [TBL] [Abstract][Full Text] [Related]
8. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. Zawacki AW; Dodge A; Woo KM; Ralphe JC; Peterson AL J Clin Lipidol; 2018; 12(6):1445-1451. PubMed ID: 30150142 [TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and tolerability of long-term lipoprotein apheresis in patients with LDL- or Lp(a) hyperlipoproteinemia: Findings gathered from more than 36,000 treatments at one center in Germany. Heigl F; Hettich R; Lotz N; Reeg H; Pflederer T; Osterkorn D; Osterkorn K; Klingel R Atheroscler Suppl; 2015 May; 18():154-62. PubMed ID: 25936320 [TBL] [Abstract][Full Text] [Related]